Ignite Creation Date:
2024-05-05 @ 7:30 PM
Last Modification Date:
2024-10-26 @ 9:50 AM
Study NCT ID:
NCT00687544
Status:
TERMINATED
Last Update Posted:
2017-04-06
First Post:
2008-05-27
Brief Title:
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects Study P04469TERMINATED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Status:
TERMINATED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study adult Indonesian subjects with human immunodeficiency virus HIV coinfected with chronic hepatitis C CHC will be given peginterferon alfa-2b PEG-IFN plus ribavirin RBV combination therapy The efficacy rate sustained virologic response end of treatment virologic response and sustained biochemical response the subject morbidity rate as caused by other opportunistic infection eg bacterial pneumonia tuberculosis and other bacterial infection and the safety and tolerability of this combination therapy will be examined
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None